News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across 10 sites in India
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
The company has been sold to Shinshin Pharmaceuticals
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Subscribe To Our Newsletter & Stay Updated
